Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.40 |
| ▸ | FABP7 | O15540 | 2/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | MDM4 | O15151 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | TLR2 | O60603 | 2/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18747984 | 1.00 | KMT2A (0.41) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL27714933 | 1.00 | KMT2A (0.41) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL31688499 | 0.94 | KMT2A (0.42) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL16128222 | 0.91 | KMT2A (0.47) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL30854378 | 0.91 | KMT2A (0.47) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL15266302 | 0.91 | KMT2A (0.47) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL25355822 | 0.89 | TLR2 (0.41) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL25355812 | 0.89 | TLR2 (0.41) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL21837571 | 0.89 | KMT2A (0.41) | KMT2AFABP5FABP7CASP3EPHX2 | |
| SCHEMBL21837574 | 0.89 | KMT2A (0.41) | KMT2AFABP5FABP7CASP3EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4574166-A2 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | JANSSEN Pharmaceutica NV (BE) | 2025-06-25 | — | — | EP | disclosed |
| EP-3647319-B1 | PEPTIDE COMPOUND, APPLICATION THEREOF AND COMPOSITION CONTAINING SAME | XDCEXPLORER SHANGHAI CO LTD (CN) | 2025-04-09 | — | — | EP | disclosed |
| EP-3988123-B1 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2025-02-26 | — | — | EP | disclosed |
| US-12129312-B2 | Peptide compound, application thereof and composition containing same | XDCEXPLORER (SHANGHAI) CO., LTD. (CN) | 2024-10-29 | — | — | US | disclosed |
| WO-2024153243-A1 | MODIFIED PEPTIDE AS TREM-1 INHIBITOR | 武汉人福创新药物研发中心有限公司 | 2024-07-25 | — | — | WO | disclosed |
| CN-118359676-A | Modified peptides as Trem-1 inhibitors | 武汉人福创新药物研发中心有限公司 | 2024-07-19 | — | — | CN | disclosed |
| CN-118256591-A | Cyclic peptide compound having high membrane permeability and library comprising same | 中外制药株式会社 | 2024-06-28 | — | — | CN | disclosed |
| CN-110869544-B | Cyclic peptide compound having high membrane permeability and library comprising same | 中外制药株式会社 | 2024-03-08 | — | — | CN | disclosed |
| US-20240018208-A1 | CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-18 | — | — | US | disclosed |
| US-20230365644-A1 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-16 | — | — | US | disclosed |
| US-11767354-B2 | Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | JANSSEN PHARMACEUTICA NV (BE) | 2023-09-26 | — | — | US | disclosed |
| US-11732019-B2 | Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | JANSSEN PHARMACEUTICA NV (BE) | 2023-08-22 | — | — | US | disclosed |
| US-11591379-B2 | Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | JANSSEN PHARMACEUTICA NV (BE) | 2023-02-28 | — | — | US | disclosed |
| CN-109134610-B | Peptide compound, application thereof and composition containing peptide compound | 尚华医药科技(江西)有限公司 | 2022-07-08 | — | — | CN | disclosed |
| EP-3988123-A1 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | Janssen Pharmaceutica NV (BE) | 2022-04-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12129312-B2 | Peptide compound, application thereof and composition containing same | VIP, NGLY1, FURIN | KMT2A 4475/4885FABP5 2965/4885FABP7 2056/4885 |
| US-20240018208-A1 | CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | NPY4R, NPY5R, NPY1R | KMT2A 2517/4885FABP5 639/4885FABP7 867/4885 |
| US-11732019-B2 | Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | NPY4R, NPY5R, NPY1R | KMT2A 2517/4885FABP5 639/4885FABP7 867/4885 |
| US-11591379-B2 | Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | NPY1R, NPY5R, NPY2R | KMT2A 2481/4885FABP5 2236/4885FABP7 2292/4885 |
| US-20230365644-A1 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | NPY1R, NPY5R, NPY2R | KMT2A 2481/4885FABP5 2236/4885FABP7 2292/4885 |
| US-11767354-B2 | Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors | NPY1R, NPY5R, NPY2R | KMT2A 2481/4885FABP5 2236/4885FABP7 2292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.